| Yang, Kunyu |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
| Active, not recruiting | 2 | 30 | RoW | Tislelizumab | Wuhan Union Hospital, China, BeiGene | Esophagus Cancer, Neoadjuvant Therapy | 03/23 | 12/24 | | |
TQB2618-AK105-II-01, NCT05563480: TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nasopharyngeal Carcinoma | 10/23 | 05/24 | | |
NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | SI-B001, Paclitaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinoma | 06/25 | 06/25 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT06301165: TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 162 | RoW | TPC induction chemotherapy, GP induction chemotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/28 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
PC-1, NCT05993858: Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC |
|
|
| Not yet recruiting | 2 | 33 | RoW | 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy | Wuhan Union Hospital, China | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | 12/25 | 12/26 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
NCT06347731: Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) |
|
|
| Recruiting | N/A | 47 | RoW | Proton Radiation Therapy | Varian, a Siemens Healthineers Company | Tumor, Solid | 03/25 | 03/25 | | |
NCT05459415: Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC |
|
|
| Active, not recruiting | N/A | 54 | RoW | Reducing Excision Margins | Wuhan Union Hospital, China | Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin | 06/25 | 06/27 | | |
